Remove 2020 Remove Legal Remove Mergers and Acquisitions
article thumbnail

5 Things to Know About Canoo Stock

The Motley Fool

Canoo was not a normal IPO Canoo came public via a merger with a special purpose acquisition company (SPAC) in late 2020. That's exactly what happened, and an increasing number of the SPAC mergers from that period are now resulting in bankruptcies. Here's five reasons you should tread carefully.

article thumbnail

Is 3M Spinoff Solventum a Buy? (And What It Means for 3M Investors)

The Motley Fool

First, 3M saddled Solventum with debt to shore up the balance sheet of the former as it faces multibillion-dollar legal settlements. Third, it's worth noting that 3M Healthcare/Solventum was the focus of 3M's merger and acquisition activity over the past five years. In 2020, 3M sold the majority of its drug delivery business.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3 Predictions for Tilray Brands Stock in 2024

The Motley Fool

But I do expect there to be more excitement toward the latter half of 2024 -- an election year in the U.S. -- and that means it would be an opportunistic time for marijuana legalization to enter the discussion again. The last time Tilray's stock was in positive territory was -- you guessed it -- the 2020 election year, when it rose by 33%.

article thumbnail

MiddleGround Capital Closes $440m Continuation Vehicle

Private Equity Insights

Under Stoettner’s leadership, the company completed two acquisitions. The management team at Banner, led by Stoettner, has demonstrated the ability to maximize performance while integrating new acquisitions and expanding the geographic footprint of the business through greenfield expansion projects.

Capital 130
article thumbnail

Why Illumina Stock Zoomed Higher on Thursday

The Motley Fool

A legal opinion on the other side of Planet Earth put some juice into Illumina 's (NASDAQ: ILMN) stock on Thursday. Specifically, this was the company's $8 billion cash-and-stock deal to purchase cancer detection company Grail, agreed in 2020. In 2021, the EC blocked the deal following requests from a clutch of EU countries.

article thumbnail

Where Will Johnson & Johnson Be in 5 Years?

The Motley Fool

Top-selling drug Stelara is facing a patent cliff this year, the company has just spun off one of its business units, and there's no certainty that its legal issues will go away, either. In 2020, J&J acquired Momenta Pharmaceuticals for $6.5 Last year, it bought heart pump maker Abiomed for a more sizable $16.6 billion price tag.

article thumbnail

Robert Poirier to Lead OMERS Governance Review; OPE Acquires Integris

Pension Pulse

Frontenac bought it in 2020 and merged it with other firms to form Integris in 2021, then supported it through several acquisitions. OMERS Private Equity will support management in maintaining its impressive track record of profitable growth, both organically and through strategic acquisitions.